id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-282589-xof56j98	Lopes, M. I. F.	Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial	2020-08-11		.txt	text/plain	3972	200	53	We present the interim analysis of a single-center randomized, double-blinded, placebo controlled clinical trial of colchicine for the treatment of moderate to severe COVID-19, with 38 patients allocated 1:1 from April 11 to July 06, 2020. We conducted a randomized, double-blinded, placebo controlled clinical trial to evaluate the use of colchicine for the treatment of hospitalized patients with moderate to severe COVID-19. As secondary endpoints we assessed clinical and laboratory parameters: measures of serum CRP, serum LDH and relation neutrophil to lymphocyte of peripheral blood samples from day zero to day 7; the number, type, and severity of adverse events; frequency of interruption of the study protocol due to adverse events; and frequency of QT interval above 450 ms. Patients who received colchicine in this randomized, double-blinded, placebo controlled clinical trial presented better evolution in terms of the need for supplemental oxygen and the length of hospitalization.	./cache/cord-282589-xof56j98.txt	./txt/cord-282589-xof56j98.txt